Abstract
In “Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study,” Bar-Or et al. demonstrated a significant reduction in the number of new brain lesions in patients who were given ofatumumab compared with those who received placebo. However, Dr. Kearney notes that comparing ofatumumab to placebo, rather than a disease-modifying therapy, could have artificially inflated the benefit of ofatumumab. In addition, he questions the ethics of administering a placebo to a patient, knowing that medications proven to decrease the likelihood of disability progression are available. Bar-Or et al. responds that the results were not misleading, given that they did not claim the findings were comparable to those of studies with an active comparator. They also acknowledge that the methodology employed in this study—which was designed and executed 6 years prior to publication—would not be utilized today. In “Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study,” Bar-Or et al. demonstrated a significant reduction in the number of new brain lesions in patients who were given ofatumumab compared with those who received placebo. However, Dr. Kearney notes that comparing ofatumumab to placebo, rather than a disease-modifying therapy, could have artificially inflated the benefit of ofatumumab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
